ASCO GU 2021: Pre-Orchiectomy Serum Tumor Markers as a Predictor of Recurrence in Stage I Germ Cell Tumors

( Clinical stage 1 testicular cancer is managed surgically, with cancer-specific survival rates approaching 100%. Risk factors for recurrence vary by histology and include the size of the tumor (seminoma) and presence of lymphovascular invasion and degree of embryonal carcinoma predominance (non-seminoma). In this poster, Dr. Rohit Badia and colleagues investigated the utility of pre-orchiectomy serum tumor markers in predicting the recurrence of stage 1 testicular cancer.

To do this, the authors assembled a multi-institutional database of 150 patients with clinical stage 1 testicular germ cell tumors treated between 2006 and 2018, recording patient demographics, tumor characteristics, treatment, and serum tumor markers at various time points. Of the 150 patients, 56% had elevated tumor markers prior to orchiectomy. Patients with elevated tumor markers prior to surgery had larger tumors than those with normal tumor markers (57 mm vs 32 mm, p < 0.0001). Non-seminoma histology was marginally associated with increased recurrence risk in this cohort (p = 0.058). Patients with elevated pre-orchiectomy tumor markers did not have a significantly higher likelihood of disease recurrence, nor do these patients have statistically different recurrence-free survival (p = 0.745)


Presented by: Rohit R. Badia, University of Texas Southwestern, Dallas, TX

Written by: Alok Tewari, MD, PhD, Medical Oncologist at the Dana-Farber Cancer Institute, during the 2021 American Society of Clinical Oncology Genitourinary Cancers Symposium (#GU21), February 11th-February 13th, 2021